Quick Answer
Traws Pharma, Inc. reported Operating Income Loss of -$142.37 million for the year ending 2024.
- Traws Pharma, Inc. showed a decrease of -601.4% in Operating Income Loss from 2023 to 2024.
- This data is from Traws Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2011 to 2024 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2011 to 2024), Traws Pharma, Inc.'s Operating Income Loss has declined by 416.4%.
- Historical annual values: Fiscal year 2024: -$142.37 million | Fiscal year 2023: -$20.30 million | Fiscal year 2022: -$19.63 million | Fiscal year 2021: -$16.50 million | Fiscal year 2020: -$24.99 million | Fiscal year 2019: -$21.70 million | Fiscal year 2018: -$23.28 million | Fiscal year 2017: -$25.74 million | Fiscal year 2016: -$23.70 million | Fiscal year 2015: -$23.97 million | Fiscal year 2014: -$63.74 million | Fiscal year 2013: -$62.22 million | Fiscal year 2012: -$22.28 million | Fiscal year 2011: -$27.57 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: